ArticleJournal of Crohn's & colitis2019
High-Throughput Identification of the Plasma Proteomic Signature of Inflammatory Bowel Disease.
Article in Journal of Crohn's & colitis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Exploring peripheral immune mechanisms and potential therapeutic drugs for Alzheimer's disease.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Exploring the mechanisms of PANoptosis in osteoarthritis and the therapeutic potential of andrographolide through bioinformatics and single-cell analysis.Biology direct · 2025Article
- Article
- Plasma protein-based and polygenic risk scores serve complementary roles in predicting inflammatory bowel disease.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2025Article
- Identifying critical modules and biomarkers of intervertebral disc degeneration by using weighted gene co-expression network.JOR spine · 2024Article
- Identification of Key Disulfidptosis-Related Genes and Their Association with Gene Expression Subtypes in Crohn's Disease.Journal of inflammation research · 2024Article
- Article
- A Current State of Proteomics in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Search and Review.International journal of molecular sciences · 2023Review
- Multi-omics in Crohn's disease: New insights from inside.Computational and structural biotechnology journal · 2023Review
- Identification of Critical Modules and Biomarkers of Ulcerative Colitis by Using WGCNA.Journal of inflammation research · 2023Article
- Review of microbiota gut brain axis and innate immunity in inflammatory and infective diseases.Frontiers in cellular and infection microbiology · 2023Review
- Quantifying the role of transcript levels in mediating DNA methylation effects on complex traits and diseases.Nature communications · 2022Article
- PARK7/DJ-1 as a Therapeutic Target in Gut-Brain Axis Diseases.International journal of molecular sciences · 2022Review
- Identification of Immune-Related Gene Signature and Prediction of CeRNA Network in Active Ulcerative Colitis.Frontiers in immunology · 2022Article
- Immunomodulatory role of Parkinson's disease 7 in inflammatory bowel disease.Scientific reports · 2021Article
- Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease.Nature immunology · 2021Observational
- Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine.Journal of translational medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundThe molecular aetiology of inflammatory bowel disease [IBD] and its two subtypes, ulcerative colitis [UC] and Crohn's disease [CD], have been carefully investigated at genome and transcriptome levels. Recent advances in high-throughput proteome quantification has enabled comprehensive large-scale plasma proteomics studies of IBD.
methodsThe study used two cohorts: [1] The CERTIFI-cohort: 42 samples from the CERTIFI trial of anti-TNFα-refractory CD patients; [2] the PROgECT-UNITI-HCs cohort: 46 UC samples of the PROgECT study, 84 CD samples of the UNITI I and UNITI II studies, and 72 healthy controls recruited in Mount Sinai Hospital, New York, USA. The plasma proteome for these two cohorts was quantified using high-throughput platforms.
resultsFor the PROgECT-UNITI-HCs cohort, we measured a total of 1310 proteins. Of these, 493 proteins showed different plasma levels in IBD patients to the plasma levels in controls at 10% false discovery rate [FDR], among which 11 proteins had a fold change greater than 2. The proteins upregulated in IBD were associated with immunity functionality, whereas the proteins downregulated in IBD were associated with nutrition and metabolism. The proteomic profiles were very similar between UC and CD. In the CERTIFI cohort, 1014 proteins were measured, and it was found that the plasma protein level had little correlation with the blood or intestine transcriptomes.
conclusionsWe report the largest proteomics study to date on IBD and controls. A large proportion of plasma proteins are altered in IBD, which provides insights into the disease aetiology and indicates a potential for biomarker discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.